Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

被引:4
|
作者
Gao, Fenghua [1 ]
Zhang, Tingting [1 ]
Liu, Hengqi [1 ]
Li, Wei [1 ]
Liu, Xianming [1 ]
Qiu, Lihua [1 ]
Li, Lanfang [1 ]
Zhou, Shiyong [1 ]
Qian, Zhengzi [1 ]
Dong, Sitong [2 ]
Zhao, Sai [2 ]
Wang, Xianhuo [1 ]
Zhang, Huilai [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Lymphoma, Sino US Ctr Lymphoma & Leukemia Res,Key Lab Canc, Huanhuxi Rd, Tianjin 300060, Peoples R China
[2] Systemat Review Solut Ltd, Ingenu Ctr, Nottingham, England
基金
中国国家自然科学基金;
关键词
Follicular lymphoma; POD24; Risk factors; Meta-analysis; Systematic review; SOLUBLE INTERLEUKIN-2-RECEPTOR LEVEL; METABOLIC TUMOR VOLUME; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; PROGNOSTIC VALUE; 1ST-LINE TREATMENT; PREDICTS SURVIVAL; DIAGNOSIS; DOXORUBICIN;
D O I
10.1007/s00277-022-04914-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progression of disease within 24 months (POD24) is strongly associated with a poor outcome in patients with follicular lymphoma (FL). Our study aimed to identify the potential risk factors for POD24 in patients with FL. Medline, EMBASE and the Cochrane Library were systematically searched from the earliest record to September 2020. Studies investigating the prognostic factors for POD24 in patients with newly diagnosed grade 1-3a FL were included. Among 10,014 pieces of literature, a total of 90 studies investigating 82 risk factors were included for qualitative analysis. Meta-analyses were performed in 31 studies with 11 factors. Results showed that elevated sIL-2R, beta 2m and LDH, total metabolic tumour volume > 510 cm(3), vitamin D < 20 ng/mL, grade 3a and lymphoma-associated macrophages/high-power field >= 15 were significantly associated with an increased risk of POD24. No significant association was found between POD24 and the ALC/AMC ratio, sex, T effector signature or EZH2 genetic alteration. Additionally, minimal residual disease, Ki-67, PD-1 and TP53 were analysed narratively. Overall, this is the first study that comprehensively analysed the prognostic factors associated with POD24 in FL patients. We have confirmed the significance value of several common prognostic factors as well as others not commonly included in clinical study, helping to construct an integrated and more efficient model.
引用
收藏
页码:2383 / 2392
页数:10
相关论文
共 50 条
  • [31] Risk factors for infectiousness of patients with tuberculosis: a systematic review and meta-analysis
    Melsew, Y. A.
    Doan, T. N.
    Gambhir, M.
    Cheng, A. C.
    McBryde, E.
    Trauer, J. M.
    EPIDEMIOLOGY AND INFECTION, 2018, 146 (03): : 345 - 353
  • [32] Risk factors for mortality in patients with dengue: A systematic review and meta-analysis
    Chagas, Gabriel Cavalcante Lima
    Rangel, Amanda Ribeiro
    Noronha, Luisa Macambira
    Veloso, Felipe Camilo Santiago
    Kassar, Samir Buainain
    Oliveira, Michelle Jacintha Cavalcante
    Meneses, Gdayllon Cavalcante
    da Silva Junior, Geraldo Bezerra
    Daher, Elizabeth De Francesco
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2022, 27 (08) : 656 - 668
  • [33] Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies
    Di Minno, Matteo Nicola Dario
    Marchesini, Emanuela
    Valdre, Lelia
    BLOOD, 2015, 125 (24) : 3819 - +
  • [34] Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
    Merryman, Reid
    Belada, David
    Sureda, Anna
    Leppa, Sirpa
    Vermaat, Joost S. P.
    Holte, Harald
    Hutchings, Martin
    Lugtenburg, Pieternella
    de Vos, Sven
    Abrisqueta, Pau
    Nijland, Marcel
    Christensen, Jacob Haaber
    Wahlin, Bjorn E.
    Linton, Kim M.
    Wang, Liwei
    Abbas, Aqeel
    Rana, Ali
    Quadri, Syed
    Falchi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse
    Boyne, Devon J.
    Chua, Neil
    Owen, Carolyn
    Joe-Uzuegbu, Ofodile
    Shakir, Huma
    Gogna, Priyanka
    Jarada, Tamer N.
    Brenner, Darren R.
    Elia-Pacitti, Julia
    Ewara, Emmanuel M.
    Cheung, Winson Y.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (09): : e277 - e285
  • [36] in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses
    Czerwinski, Debra K.
    Brody, Joshua
    Kohrt, Holbrook E.
    Hoppe, Richard T.
    Advani, Ranjana H.
    Levy, Ronald
    BLOOD, 2012, 120 (21)
  • [37] Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis
    Al Khabori, Murtadha
    de Almeida, John R.
    Guyatt, Gordon H.
    Kuruvilla, John
    Crump, Michael
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (01): : 18 - 28
  • [38] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
    Sortais, Clara
    Lok, Anne
    Tessoulin, Benoit
    Gastinne, Thomas
    Mahe, Beatrice
    Dubruille, Viviane
    Blin, Nicolas
    Touzeau, Cyrille
    Moreau, Anne
    Bossard, Celine
    Peterlin, Pierre
    Garnier, Alice
    Guillaume, Thierry
    Le Bourgeois, Amandine
    Chevallier, Patrice
    Moreau, Philippe
    Leux, Christophe
    Le Gouill, Steven
    ANNALS OF HEMATOLOGY, 2020, 99 (07) : 1595 - 1604
  • [39] Risk factors of microtia: A systematic review and meta-analysis
    Tripathee S.
    Zhang J.
    Xiong M.
    European Journal of Plastic Surgery, 2016, 39 (5) : 335 - 344
  • [40] Risk Factors for Dyspepsia: Systematic Review and Meta-Analysis
    Marwaha, Avantika
    Ford, Alexander C.
    Lim, Allen
    Moayyedi, Paul
    GASTROENTEROLOGY, 2009, 136 (05) : A58 - A58